Trevena, Inc.

Today's conference is scheduled to begin shortly. Please continue to stand by and thank you for your patience. Thank you. Thank you. Good day, and thank you for standing by. Welcome to the Trita Third Quarter 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during this session, you'll need to press star 1 on your telephone. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Barry Shen, Senior Vice President and Chief Financial Officer. Please go ahead.

Good morning and welcome everyone. With me today are Kerry Bordeaux, our President and CEO, Patty Drake, our newly announced Chief Commercial Officer, Bob Yoder, our Chief Business Officer and Head of Commercial Operations, and our Chief Medical Officer, Mark Demitrak. We're also joined by Dr. Paul Ryder from the University of South Alabama. Dr. Ryder will share his firsthand experience with Olindic, both as an investigator in our Phase III Open Label Safety Study and in this colorectal surgery practice where Olindic is approved for use. At the end of the call, we'll open it up for questions. As a reminder, Olindic is approved in adults for the management of acute pain severe enough to require an IV opioid analgesic and for whom alternative treatments are inadequate. The important safety information including the box warning and the full prescribing information are all available on olindic.com. Also, we'll be making forward-looking statements within the meaning of federal securities law. These statements are subject to risks and uncertainties related to our business, including those covered in our filings with the SEC. We undertake no obligation to update these statements beyond today. I'll now turn the call over to Carrie for an overview of our third quarter and recent business accomplishment. Carrie?

Thank you, Barry. Good morning, everyone, and thanks for joining us today. Over the past quarter, we continue to make progress launching Olindic despite the pandemic. And we have a number of exciting announcements to make today that we strongly believe will position us for success in 2022. First, as you may have seen in our press release last week, we are thrilled to announce that Patty Drake, a seasoned biopharma executive with over 30 years of sales and marketing marketing experience will be joining Trevena as chief commercial officer. While at Merck, Patty led the successful launch of numerous hospital and specialty commercial products. Recently, Patty has been serving as a consultant to Trevena, partnering with Bob to assess the landscape and putting together a plan for commercial success. Key components of the plan include an accelerated focus on integrated health systems to drive formulary adoption, the addition of burn care as a target specialty, and optimizing the field sales organization. Patty is with us today and will speak in more detail about her plans. Importantly, Patty coming on board will allow Bob to focus on commercial operations for Olimbic and our growing pipeline. We also announced today a new study designed to assess the impact of Olimbic on cognitive function compared to IV morphine. We're initiating this study based on the positive feedback we continue to hear from physicians. And you'll hear directly from one of those physicians today, Dr. Paul Reiter, who will share his experiences treating patients with a limbic. In addition, later on the call, Mark will provide details about the two ongoing Olympic studies we're conducting to further evaluate its clinical profile and the important progress we've made with our pipeline this quarter. With that, Let me turn the call over to Patty to say a few words about the Alimbic launch.